Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1

L. M. Frenkel, M. K. Cowles, D. E. Shapiro, A. J. Melvin, D. H. Watts, C. McLellan, K. Mohan, B. Murante, S. Burchett, Y. J. Bryson, M. J. O'Sullivan, Charles D Mitchell, D. Landers

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

To gain insight into the protective effects of the three components of the zidovudine regimen used in AIDS Clinical Trial Group (ACTG) 076 on mother-to-infant transmission of human immunodeficiency virus (HIV) type 1, 188 zidovudine-treated women and their untreated infants from five HIV-1 obstetric centers were retrospectively studied. The overall rate of mother- to-infant transmission was 12.3% (95% confidence interval [CI], 7.9%- 18.0%). When the 38 women with <200 CD4 cells/μL were excluded, the mother- to-infant transmission rate was 8.8% (95% CI, 4.6%-14.8%). This rate compares favorably with the 8.3% transmission in the zidovudine arm of the ACTG 076 study. Apart from low (<200/μL) maternal CD4 cells (P = .016), no factors, including the duration of zidovudine therapy during gestation and intravenous administration of zidovudine during labor, affected the rate of mother-to-infant transmission. These findings suggest that antenatal oral zidovudine may be as effective as antenatal oral plus intravenous zidovudine during labor and the three-component ACTG 076 regimen in decreasing mother- to-infant HIV-1 transmission.

Original languageEnglish
Pages (from-to)971-974
Number of pages4
JournalJournal of Infectious Diseases
Volume175
Issue number4
StatePublished - Apr 11 1997
Externally publishedYes

Fingerprint

Zidovudine
HIV-1
Acquired Immunodeficiency Syndrome
Mothers
Clinical Trials
Confidence Intervals
Intravenous Administration
Obstetrics
Pregnancy

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. / Frenkel, L. M.; Cowles, M. K.; Shapiro, D. E.; Melvin, A. J.; Watts, D. H.; McLellan, C.; Mohan, K.; Murante, B.; Burchett, S.; Bryson, Y. J.; O'Sullivan, M. J.; Mitchell, Charles D; Landers, D.

In: Journal of Infectious Diseases, Vol. 175, No. 4, 11.04.1997, p. 971-974.

Research output: Contribution to journalArticle

Frenkel, LM, Cowles, MK, Shapiro, DE, Melvin, AJ, Watts, DH, McLellan, C, Mohan, K, Murante, B, Burchett, S, Bryson, YJ, O'Sullivan, MJ, Mitchell, CD & Landers, D 1997, 'Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1', Journal of Infectious Diseases, vol. 175, no. 4, pp. 971-974.
Frenkel, L. M. ; Cowles, M. K. ; Shapiro, D. E. ; Melvin, A. J. ; Watts, D. H. ; McLellan, C. ; Mohan, K. ; Murante, B. ; Burchett, S. ; Bryson, Y. J. ; O'Sullivan, M. J. ; Mitchell, Charles D ; Landers, D. / Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. In: Journal of Infectious Diseases. 1997 ; Vol. 175, No. 4. pp. 971-974.
@article{f7cb12ab32c04fb487176494b51b55f4,
title = "Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1",
abstract = "To gain insight into the protective effects of the three components of the zidovudine regimen used in AIDS Clinical Trial Group (ACTG) 076 on mother-to-infant transmission of human immunodeficiency virus (HIV) type 1, 188 zidovudine-treated women and their untreated infants from five HIV-1 obstetric centers were retrospectively studied. The overall rate of mother- to-infant transmission was 12.3{\%} (95{\%} confidence interval [CI], 7.9{\%}- 18.0{\%}). When the 38 women with <200 CD4 cells/μL were excluded, the mother- to-infant transmission rate was 8.8{\%} (95{\%} CI, 4.6{\%}-14.8{\%}). This rate compares favorably with the 8.3{\%} transmission in the zidovudine arm of the ACTG 076 study. Apart from low (<200/μL) maternal CD4 cells (P = .016), no factors, including the duration of zidovudine therapy during gestation and intravenous administration of zidovudine during labor, affected the rate of mother-to-infant transmission. These findings suggest that antenatal oral zidovudine may be as effective as antenatal oral plus intravenous zidovudine during labor and the three-component ACTG 076 regimen in decreasing mother- to-infant HIV-1 transmission.",
author = "Frenkel, {L. M.} and Cowles, {M. K.} and Shapiro, {D. E.} and Melvin, {A. J.} and Watts, {D. H.} and C. McLellan and K. Mohan and B. Murante and S. Burchett and Bryson, {Y. J.} and O'Sullivan, {M. J.} and Mitchell, {Charles D} and D. Landers",
year = "1997",
month = "4",
day = "11",
language = "English",
volume = "175",
pages = "971--974",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1

AU - Frenkel, L. M.

AU - Cowles, M. K.

AU - Shapiro, D. E.

AU - Melvin, A. J.

AU - Watts, D. H.

AU - McLellan, C.

AU - Mohan, K.

AU - Murante, B.

AU - Burchett, S.

AU - Bryson, Y. J.

AU - O'Sullivan, M. J.

AU - Mitchell, Charles D

AU - Landers, D.

PY - 1997/4/11

Y1 - 1997/4/11

N2 - To gain insight into the protective effects of the three components of the zidovudine regimen used in AIDS Clinical Trial Group (ACTG) 076 on mother-to-infant transmission of human immunodeficiency virus (HIV) type 1, 188 zidovudine-treated women and their untreated infants from five HIV-1 obstetric centers were retrospectively studied. The overall rate of mother- to-infant transmission was 12.3% (95% confidence interval [CI], 7.9%- 18.0%). When the 38 women with <200 CD4 cells/μL were excluded, the mother- to-infant transmission rate was 8.8% (95% CI, 4.6%-14.8%). This rate compares favorably with the 8.3% transmission in the zidovudine arm of the ACTG 076 study. Apart from low (<200/μL) maternal CD4 cells (P = .016), no factors, including the duration of zidovudine therapy during gestation and intravenous administration of zidovudine during labor, affected the rate of mother-to-infant transmission. These findings suggest that antenatal oral zidovudine may be as effective as antenatal oral plus intravenous zidovudine during labor and the three-component ACTG 076 regimen in decreasing mother- to-infant HIV-1 transmission.

AB - To gain insight into the protective effects of the three components of the zidovudine regimen used in AIDS Clinical Trial Group (ACTG) 076 on mother-to-infant transmission of human immunodeficiency virus (HIV) type 1, 188 zidovudine-treated women and their untreated infants from five HIV-1 obstetric centers were retrospectively studied. The overall rate of mother- to-infant transmission was 12.3% (95% confidence interval [CI], 7.9%- 18.0%). When the 38 women with <200 CD4 cells/μL were excluded, the mother- to-infant transmission rate was 8.8% (95% CI, 4.6%-14.8%). This rate compares favorably with the 8.3% transmission in the zidovudine arm of the ACTG 076 study. Apart from low (<200/μL) maternal CD4 cells (P = .016), no factors, including the duration of zidovudine therapy during gestation and intravenous administration of zidovudine during labor, affected the rate of mother-to-infant transmission. These findings suggest that antenatal oral zidovudine may be as effective as antenatal oral plus intravenous zidovudine during labor and the three-component ACTG 076 regimen in decreasing mother- to-infant HIV-1 transmission.

UR - http://www.scopus.com/inward/record.url?scp=16944361839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944361839&partnerID=8YFLogxK

M3 - Article

VL - 175

SP - 971

EP - 974

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -